Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATRA Atara Biotherapeutics	$7.88 -0.8%	$7.53	$5.01 ▼ $18.71	$47.33M	0.19	123,046 shs	16,739 shs
MESO Mesoblast	$10.16 -2.7%	$11.31	$5.78 ▼ $22.00	$1.33B	2.41	274,016 shs	403,844 shs
MOLN Molecular Partners	$3.58 -8.0%	$3.89	$3.36 ▼ $12.22	$157.06M	1.12	15,367 shs	3,191 shs
VIGL Vigil Neuroscience	$7.94 +0.3%	$4.80	$1.31 ▼ $7.95	$369.64M	3.4	743,926 shs	707,827 shs

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATRA Atara Biotherapeutics	-0.76%	-8.16%	+10.36%	+13.87%	-4.25%
MESO Mesoblast	-2.68%	-17.40%	-6.36%	-27.99%	+44.94%
MOLN Molecular Partners	-2.74%	-6.92%	-11.69%	-8.44%	-62.71%
VIGL Vigil Neuroscience	+0.25%	+0.76%	+0.63%	+353.71%	+105.70%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATRA Atara Biotherapeutics	4.0093 of 5 stars	3.3	3.0	4.7	0.6	2.5	0.6
MESO Mesoblast	2.5768 of 5 stars	3.5	3.0	0.0	2.8	0.8	0.6
MOLN Molecular Partners	2.3222 of 5 stars	3.8	5.0	0.0	0.0	0.0	0.6
VIGL Vigil Neuroscience	3.5359 of 5 stars	4.0	5.0	0.0	1.4	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATRA Atara Biotherapeutics	2.57	Moderate Buy	$17.75	125.25% Upside
MESO Mesoblast	3.00	Buy	$18.00	77.17% Upside
MOLN Molecular Partners	3.50	Strong Buy	$12.00	235.20% Upside
VIGL Vigil Neuroscience	2.00	Hold	$10.80	36.02% Upside

Current Analyst Ratings Breakdown

Latest ATRA, MESO, MOLN, and VIGL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/28/2025	VIGL Vigil Neuroscience	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$11.00 ➝ $8.00
5/27/2025	VIGL Vigil Neuroscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$14.00 ➝ $8.00
5/23/2025	VIGL Vigil Neuroscience	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/22/2025	VIGL Vigil Neuroscience	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold
5/22/2025	VIGL Vigil Neuroscience	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Neutral	$8.00
5/22/2025	VIGL Vigil Neuroscience	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Market Perform
5/22/2025	VIGL Vigil Neuroscience	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/22/2025	VIGL Vigil Neuroscience	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/22/2025	VIGL Vigil Neuroscience	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Perform
5/22/2025	VIGL Vigil Neuroscience	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$13.00 ➝ $8.00
3/31/2025	MESO Mesoblast	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATRA Atara Biotherapeutics	$128.94M	0.36	N/A	N/A	($16.89) per share	-0.47
MESO Mesoblast	$5.90M	220.04	N/A	N/A	$4.21 per share	2.41
MOLN Molecular Partners	$5.65M	25.59	N/A	N/A	$3.99 per share	0.90
VIGL Vigil Neuroscience	N/A	N/A	N/A	N/A	$1.75 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATRA Atara Biotherapeutics	-$85.40M	-$3.72	N/A	N/A	N/A	-7.83%	N/A	-14.51%	8/11/2025 (Estimated)
MESO Mesoblast	-$87.96M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/29/2025 (Estimated)
MOLN Molecular Partners	-$61.39M	-$1.92	N/A	N/A	N/A	-1,043.01%	-42.20%	-38.12%	8/25/2025 (Estimated)
VIGL Vigil Neuroscience	-$84.26M	-$2.05	N/A	N/A	N/A	N/A	-111.70%	-74.67%	8/12/2025 (Estimated)

Latest ATRA, MESO, MOLN, and VIGL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	ATRA Atara Biotherapeutics	-$3.07	$3.50	+$6.57	$3.50	$4.30 million	$98.10 million
5/15/2025	Q1 2025	MOLN Molecular Partners	-$0.3855	-$0.50	-$0.1145	-$0.50	N/A	N/A
5/7/2025	Q1 2025	VIGL Vigil Neuroscience	-$0.53	-$0.49	+$0.04	-$0.49	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATRA Atara Biotherapeutics	N/A	N/A	N/A	N/A	N/A
MESO Mesoblast	N/A	N/A	N/A	N/A	N/A
MOLN Molecular Partners	N/A	N/A	N/A	N/A	N/A
VIGL Vigil Neuroscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATRA Atara Biotherapeutics	N/A	0.57	0.57
MESO Mesoblast	0.22	0.96	0.63
MOLN Molecular Partners	N/A	15.28	15.28
VIGL Vigil Neuroscience	N/A	2.97	2.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATRA Atara Biotherapeutics	70.90%
MESO Mesoblast	1.43%
MOLN Molecular Partners	26.55%
VIGL Vigil Neuroscience	83.64%

Insider Ownership

Company	Insider Ownership
ATRA Atara Biotherapeutics	4.00%
MESO Mesoblast	18.80%
MOLN Molecular Partners	5.93%
VIGL Vigil Neuroscience	18.01%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATRA Atara Biotherapeutics	330	5.96 million	5.72 million	Optionable
MESO Mesoblast	80	127.78 million	103.76 million	Optionable
MOLN Molecular Partners	180	40.38 million	37.98 million	Not Optionable
VIGL Vigil Neuroscience	40	46.67 million	38.27 million	Not Optionable

ATRA, MESO, MOLN, and VIGL Headlines

Recent News About These Companies

Vigil Neuroscience, Inc. (NASDAQ:VIGL) Receives $10.80 Consensus Price Target from Analysts

June 20, 2025 | americanbankingnews.com

Vigil Neuroscience, Inc. (NASDAQ:VIGL) Receives Consensus Rating of "Hold" from Analysts

June 17, 2025 | marketbeat.com

Two Sigma Investments LP Acquires 41,836 Shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL)

June 12, 2025 | marketbeat.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HURA and VIGL on Behalf of Shareholders

June 9, 2025 | prnewswire.com

Wall Street Analysts Think Vigil Neuroscience (VIGL) Could Surge 26.9%: Read This Before Placing a Bet

June 9, 2025 | zacks.com

Squarepoint Ops LLC Acquires New Shares in Vigil Neuroscience, Inc. (NASDAQ:VIGL)

June 9, 2025 | marketbeat.com

Millennium Management LLC Boosts Holdings in Vigil Neuroscience, Inc. (NASDAQ:VIGL)

June 9, 2025 | marketbeat.com

Jane Street Group LLC Invests $83,000 in Vigil Neuroscience, Inc. (NASDAQ:VIGL)

June 9, 2025 | marketbeat.com

Vigil Neuroscience, Inc. (NASDAQ:VIGL) Holdings Lifted by Two Sigma Advisers LP

June 8, 2025 | marketbeat.com

Vigil Neuroscience halts Phase 2 trial for ALSP treatment

June 5, 2025 | investing.com

Vigil’s TREM2 Antibody for Rare Brain Disease Flunks Phase II Trial

June 5, 2025 | biospace.com

VIGIL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation into Fairness of Vigil Neuroscience, Inc. (NASDAQ: VIGL) Proposed Shareholder Buyout and Encourages Investors ...

June 5, 2025 | morningstar.com

Disappointing results see Vigil Neuro drop iluzanebart development

June 4, 2025 | thepharmaletter.com

VIGIL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation into Fairness of Vigil Neuroscience, Inc. (NASDAQ: VIGL) Proposed Shareholder Buyout and Encourages Investors to Contact the Firm

June 4, 2025 | prnewswire.com

Vigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSP

June 4, 2025 | globenewswire.com

Should You Buy Vigil Neuroscience, Inc. (VIGL) After Golden Cross?

June 2, 2025 | zacks.com

HC Wainwright Has Bearish Forecast for VIGL FY2026 Earnings

May 30, 2025 | marketbeat.com

Stifel cuts Vigil Neuroscience stock rating, lowers target to $8

May 29, 2025 | investing.com

Vigil Neuroscience (NASDAQ:VIGL) Downgraded by Stifel Nicolaus to Hold

May 29, 2025 | marketbeat.com

Stifel Downgrades Vigil Neuroscience (VIGL)

May 29, 2025 | msn.com

HC Wainwright Reiterates "Neutral" Rating for Vigil Neuroscience (NASDAQ:VIGL)

May 28, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATRA, MESO, MOLN, and VIGL Company Descriptions

Atara Biotherapeutics NASDAQ:ATRA

$7.88 -0.06 (-0.76%)

Closing price 06/23/2025 04:00 PM Eastern

Extended Trading

$8.06 +0.18 (+2.22%)

As of 04:19 AM Eastern

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Mesoblast NASDAQ:MESO

$10.16 -0.28 (-2.68%)

Closing price 06/23/2025 04:00 PM Eastern

Extended Trading

$10.42 +0.26 (+2.55%)

As of 07:00 AM Eastern

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Molecular Partners NASDAQ:MOLN

$3.60 -0.29 (-7.33%)

As of 06/23/2025 04:00 PM Eastern

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Vigil Neuroscience NASDAQ:VIGL

$7.94 +0.02 (+0.25%)

Closing price 06/23/2025 04:00 PM Eastern

Extended Trading

$7.94 +0.00 (+0.06%)

As of 06/23/2025 07:18 PM Eastern

Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time